Company / Operating Cash Flow
Niagen Bioscience, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$13.5M
FY2025
5-year range
-$24.2M / $13.5M
FY2021-FY2025
Trend
+89.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has increased for 3 consecutive years, from -$24M in FY2022 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025.
Improved from -$15M to $14M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Niagen Bioscience, Inc.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 89.7% year-over-year.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.5M | +89.7% |
| FY2024 | $7.1M | +147.1% |
| FY2023 | -$15.1M | +37.5% |
| FY2022 | -$24.2M | -128.0% |
| FY2021 | -$10.6M | +48.1% |
| FY2020 | -$20.4M | +0.0% |
| FY2019 | -$20.4M | -108.5% |
| FY2018 | -$9.8M | +0.0% |
| FY2017 | -$9.8M | -233.9% |
| FY2016 | -$2.9M | -39.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026